APA (7th ed.) Citation

KH, L., RC, L., IL, C., SH, F., MY, T., & SF, Y. (2026). Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How? Clinical pharmacology and therapeutics, 120(2), 334. https://doi.org/10.1002/cpt.70323

Chicago Style (17th ed.) Citation

KH, Lu, Lin RC, Chang IL, Fu SH, Tsai MY, and Yang SF. "Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?" Clinical Pharmacology and Therapeutics 120, no. 2 (2026): 334. https://doi.org/10.1002/cpt.70323.

MLA (9th ed.) Citation

KH, Lu, et al. "Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?" Clinical Pharmacology and Therapeutics, vol. 120, no. 2, 2026, p. 334, https://doi.org/10.1002/cpt.70323.